EGElena Greenfeld

Elena Greenfeld

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elena Greenfeld has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • David Chitayat

    Department of Obstetrics & Gynaecology, Sinai Health System, Toronto, ON, Canada

    3 shared publications
  • Abdul Noor

    Affiliations Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada

    2 shared publications
  • Aaron R. Wheeler

    Department of Chemistry, University of Toronto, Toronto, ON, Canada

    1 shared publication
  • Andrew Wong

    Division of Diagnostic Medical Genetics Department of Pathology and Lab Medicine Mount Sinai Hospital Toronto Ontario Canada

    1 shared publication
  • Brendan Mullen

    Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, CAN

    1 shared publication
  • Chloe Mighton

    Division of Diagnostic Medical Genetics Department of Pathology and Lab Medicine Mount Sinai Hospital Toronto Ontario Canada

    1 shared publication

Latest Publications

  • Open Access

    A digital microfluidic platform for cell-based non-invasive testing

    by Dylan Siriwardena, Michael D.M. Dryden, M. Dean Chamberlain, Chloe Taylor, Louise Dupoiron, Shriya Gulati, Farhana Abbas, Julian Lamanna, David Chitayat, Aaron R. Wheeler, et al.

  • Validation of low‐pass genome sequencing for prenatal diagnosis

    by Chloe Mighton, Abdul Noor, Nicholas Watkins, Vanessa Di Gioacchino, Jordan Lerner‐Ellis, Andrew Wong, Elvira Mukharryamova, Nina Anggala, David Chitayat, Elena Greenfeld

    Objective: Chromosomal microarray (CMA), while considered the gold standard for detecting copy number variants (CNVs) in prenatal diagnostics, has its limitations, including the necessity to replace aging microarray equipment, low throughput, a static design, and an inefficient multi‐day workflow. This study evaluates the feasibility of low‐pass genome sequencing (LP‐GS) as a potential replacement for CMA in prenatal diagnostics.Methods: We comprehensively compared LP‐GS at 10x and 5x average depths with CMA in a prenatal laboratory. We examined parameters, including concordance, sensitivity, specificity, workflow efficiency, and cost‐effectiveness.Results: We found a high degree of agreement between LP‐GS and CMA for detecting CNVs and absence of heterozygosity. Furthermore, compared to CMA, LP‐GS increased workflow efficiency and proved to be cost‐neutral at 10x and cost‐effective at 5x.Conclusion: Our study suggests that LP‐GS is a promising alternative to CMA in prenatal diagnostics, offering advantages, including a more efficient workflow and scalability for larger testing volumes. Importantly, for clinical laboratories that have adopted next‐generation sequencing in a separate capacity, LP‐GS facilitates a unified NGS‐centric approach, enabling workflow consolidation. By offering a single, streamlined platform for detecting a broad range of genetic variants, LP‐GS may represent a critical step toward enhancing the diagnostic capabilities of prenatal laboratories.


  • Open Access

    Uncovering the Association Between Complete AZFc Microduplications and Spermatogenic Ability: The First Reported Series

    by Kian Asanad, Elena Greenfeld, Stephen W. Scherer, Ryan Yuen, Christian R. Marshall, Kirk Lo, Brendan Mullen, Susan Lau, Keith A. Jarvi, Mary K. Samplaski

    Purpose This article aims to report the first series of men with complete AZFc microduplications and their clinical and reproductive characteristics. Methods We sampled 3000 men who presented for reproductive urology evaluation from 2012-2020, of which 104 men underwent high-resolution Y-chromosome microarray testing, and five men were identified to have complete AZFc microduplications. Medical, surgical, and reproductive histories were obtained. Semen and hormonal parameters as well as response to fertility therapies were recorded. Results Five men were identified as having complete AZFc microduplications. The mean age was 33.75 years, representing 0.2% (5/3000) of men presenting for fertility investigation, 4.8% (5/104) of men undergoing microarray testing, and 21% (5/24) of men with AZFc abnormalities. Two of the men had prior undescended testicles and one had several autoimmune processes. The mean follicle-stimulating hormone (FSH) was 5.5 IU/L, luteinizing hormone (LH) 3.6 IU/L, and testosterone 14.56 nmol/L. One man was azoospermic, one man alternated between severe oligospermia and rare non-motile sperm, one had variable parameters, with one semen analysis demonstrating azoospermia and a second demonstrating a total motile sperm count (TMSC) of 4 ×106, one man was persistently oligospermic with TMSCs ranging 3.96-12.6 ×106, and one man initially had severe oligospermia, with a mean TMSC of 1.5 ×106, which increased to 21.7 ×106 after intervention (varicocele embolization, clomiphene citrate). This last man then fathered a spontaneous pregnancy. Conclusion AZFc complete microduplications are a rare cause of spermatogenic failure but not an uncommon form of AZFc abnormality. Clinically, they represent a heterogeneous group, having a variable reproductive potential. Cases should be managed on an individual basis.


  • Open Access

    Role of comprehensive cytogenomic investigation in successful reproductive outcome of parental small neocentromeric supernumerary ring chromosome: A case report

    by Yiming Wang, Joanna Lazier, Diane Myles‐Reid, Abdul Noor, David Chitayat, Elena Greenfeld

    Small supernumerary marker chromosomes (sSMC) can form small supernumerary ring chromosomes (sSRC). Loss of parentally inherited sSRC containing vital gene content may cause an “unbalanced” karyotype and fetal microdeletion syndromes. Rarely, sSRC with neocentromere can be inherited, leading to a “balanced” karyotype, which can be diagnosed with preimplantation genetic testing.